What Is Sublingual Immunotherapy? A Clinical Definition

It depends on the form. FDA-approved sublingual immunotherapy exists only as tablets for specific single allergens: Grastek and Oralair for grass pollen, Ragwitek for ragweed, and Odactra for house dust mite. These were approved starting in 2014. Custom liquid allergy drops, which can be compounded to cover multiple allergens in one formula, are different and are used off-label in the United States, meaning the sublingual use of compounded multi-allergen drops has not been FDA-approved. Off-label prescribing is common and legal across medicine, but it does mean liquid drops carry less regulatory oversight than the approved tablets and are generally not covered by insurance. The distinction is important when comparing your options.

Sublingual immunotherapy is primarily used for allergic rhinitis and allergic rhinoconjunctivitis, the hay-fever-type symptoms caused by inhaled allergens such as tree, grass, and weed pollens, dust mites, and animal dander. The evidence is strongest for these conditions. SLIT may also help some people with allergic asthma when it accompanies allergic rhinitis, though it is not a standalone asthma treatment and uncontrolled asthma is actually a contraindication. Food sublingual immunotherapy is investigational, with weaker evidence than for environmental allergies, so it is not a routine treatment. A clinician confirms through testing and history whether your condition is one SLIT can realistically address, since it only works against allergens you genuinely react to.

Sublingual immunotherapy is generally well tolerated, and most side effects are mild and confined to the area where the dose is held. Common reactions include itching or tingling of the mouth, lips, tongue, or ears, mild swelling, and occasional stomach upset, and these often lessen as the body adjusts over the first weeks. A 2024 meta-analysis found local reactions in roughly 40.8 percent of patients, while fewer than 0.1 percent of patients in the program have systemic reactions. Serious reactions such as anaphylaxis are exceptionally rare with SLIT. Even so, no immunotherapy is entirely without risk, and a clinician should review your history, identify any contraindications such as eosinophilic esophagitis, and explain warning signs before you begin.

Sublingual immunotherapy is a long-term treatment, not a short course. Most allergists recommend taking it daily for roughly three to five years to build tolerance that can last after treatment stops. The early phase aims to reach a steady maintenance dose, and the remaining years consolidate the immune changes so the benefit becomes durable. Stopping too soon, before that tolerance is established, makes it more likely that symptoms gradually return. The exact length is individualized and decided with your provider based on how you respond. Because the treatment depends on steady, repeated exposure, daily consistency over the full course is one of the most important factors in achieving lasting results.

Both reduce allergy symptoms, but they have different evidence profiles, and the honest answer is that head-to-head superiority is not firmly established. Allergy shots have the longest and largest body of research and are sometimes considered to produce somewhat greater symptom reduction for certain allergens, though comparisons vary by study and allergen. Sublingual immunotherapy has solid moderate-grade evidence of its own and a clear practical advantage: it is needle-free, taken at home, and carries a lower risk of systemic reactions. Rather than ranking one as universally better, clinicians weigh the allergens involved, your preference for needles versus daily home dosing, safety considerations, and convenience. For many people the more relevant question is which they will actually stick with for several years, since consistency drives results.